Global Parathyroid Disorders Market Growth (Status and Outlook) 2023-2029

Global Parathyroid Disorders Market Growth (Status and Outlook) 2023-2029

Parathyroid disorders lead to abnormal levels of calcium in the blood that can cause brittle bones, kidney stones, fatigue, weakness, and other problems.

LPI (LP Information)' newest research report, the “Parathyroid Disorders Industry Forecast” looks at past sales and reviews total world Parathyroid Disorders sales in 2022, providing a comprehensive analysis by region and market sector of projected Parathyroid Disorders sales for 2023 through 2029. With Parathyroid Disorders sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Parathyroid Disorders industry.

This Insight Report provides a comprehensive analysis of the global Parathyroid Disorders landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Parathyroid Disorders portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Parathyroid Disorders market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Parathyroid Disorders and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Parathyroid Disorders.

The global Parathyroid Disorders market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Patients with chronic kidney disease may develop secondary hyperparathyroidism with resultant chronic kidney disease-mineral and bone disorder. Hypoparathyroidism most often occurs after neck surgery; it can also be caused by autoimmune destruction of the glands and other less common problems. Evaluation of patients with abnormal serum calcium levels includes a history and physical examination; repeat measurement of serum calcium level; and measurement of creatinine, magnesium, vitamin D, and parathyroid hormone levels. The treatment for symptomatic primary hyperparathyroidism is parathyroidectomy. Management of asymptomatic primary hyperparathyroidism includes monitoring symptoms; serum calcium and creatinine levels; and bone mineral density. Patients with hypoparathyroidism require close monitoring and vitamin D (e.g., calcitriol) replacement.

This report presents a comprehensive overview, market shares, and growth opportunities of Parathyroid Disorders market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Hyperparathyroidism
Parathyroid Cancer
Hypoparathyroidism

Segmentation by application
Hospitals
Specialty Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Alcon Laboratories
Amgen
Bayer Healthcare
Becton, Dickinson and Company
Eli Lilly
Ethicon

Please note: The report will take approximately 2 business days to prepare and deliver.